KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Work In Process (2022 - 2025)

Sarepta Therapeutics (SRPT) has 4 years of Work In Process data on record, last reported at $885.4 million in Q3 2025.

  • For Q3 2025, Work In Process rose 83.63% year-over-year to $885.4 million; the TTM value through Sep 2025 reached $885.4 million, up 83.63%, while the annual FY2024 figure was $610.7 million, 91.77% up from the prior year.
  • Work In Process reached $885.4 million in Q3 2025 per SRPT's latest filing, up from $802.9 million in the prior quarter.
  • Across five years, Work In Process topped out at $885.4 million in Q3 2025 and bottomed at $269.2 million in Q4 2022.
  • Average Work In Process over 4 years is $575.2 million, with a median of $546.4 million recorded in 2024.
  • Peak YoY movement for Work In Process: rose 18.3% in 2023, then surged 91.77% in 2024.
  • A 4-year view of Work In Process shows it stood at $269.2 million in 2022, then increased by 18.3% to $318.5 million in 2023, then soared by 91.77% to $610.7 million in 2024, then soared by 44.99% to $885.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Work In Process were $885.4 million in Q3 2025, $802.9 million in Q2 2025, and $762.2 million in Q1 2025.